Simplex Trading’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Simplex Trading’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-333	Closed	-$9K	–	11444
2022 Q1	$9K	Sell	333 -107	-24%	-$3.01K	﹤0.01%	9006
2021 Q4	$15K	Sell	440 -3,262	-88%	-$122K	﹤0.01%	8713
2021 Q3	$147K	Hold	3,702	–	–	﹤0.01%	6062
2021 Q2	$148K	Sell	3,702 -160	-4%	-$5.97K	﹤0.01%	6158
2021 Q1	$137K	Sell	3,862 -2,103	-35%	-$78.9K	﹤0.01%	5307
2020 Q4	$185K	Buy	+5,965	New	+$182K	﹤0.01%	4725

Other funds holding GERM

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Simplex Trading's GERM Position: Q2 2022 in Review

Simplex Trading sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q2 2022, closing a stake of 333 shares — an estimated $9K sold.

Simplex Trading first reported a position in GERM in Q4 2020 and held it in 6 quarters. The position peaked at $185K in Q4 2020. 25 funds tracked by Wall St. Rank hold GERM as of Q2 2022.

Simplex Trading reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q2 2022 after selling out during the quarter.
Simplex Trading sold 333 Amplify Treatments, Testing and Advancements ETF shares in Q2 2022, an estimated $9K.
Simplex Trading first reported a position in Amplify Treatments, Testing and Advancements ETF in Q4 2020 and held it in 6 quarters.
Simplex Trading's Amplify Treatments, Testing and Advancements ETF position peaked at $185K in Q4 2020.
25 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q2 2022.

Based on Simplex Trading's 13F filing for Q2 2022, filed 3 Aug 2022.